{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T14:13:12Z","timestamp":1770819192339,"version":"3.50.1"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2005,9,11]],"date-time":"2005-09-11T00:00:00Z","timestamp":1126396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,9,11]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Uncontrolled studies have found intravenous immunoglobulin (IVIG) to be effective in the treatment of pemphigus vulgaris (PV). The aim of this study was to evaluate the role of IVIG in preventing IgG autoantibodies binding to desmoglein-3 and blister formation using a controlled experimental design. The ability of IVIG to affect the binding of IgG affinity purified from two patients with PV to desmoglein-3 in comparison to IgG from one donor, was conducted by enzyme-linked immunosorbent assay (ELISA). The specificity was confirmed by competition assay. We assessed the effect of IVIG on the induction of experimental-PV in CD1 newborn mice by subcutaneous subjection of IgG affinity purified from two patients with PV. The treatment was conducted by subcutaneous administration of IVIG together with IgG from the pemphigus patients or appropriate control. The skin of the newborns was examined 24\u201348\u2003h later for blisters, and samples of the affected areas were analysed by immunohistochemistry. IVIG as a whole molecule and its F(ab)2 portion inhibited the binding of anti-desmoglein-3 antibody to recombinant desmoglein-3 in a dose-dependent manner. The specificity was confirmed by competition assays. In-vivo, IVIG and its F(ab)2 portion prevented blister formation in the newborn mice. Cutaneous lesions were noted only in the groups of newborn mice who were injected with IgG fractions from the PV patients. Immunopathological evaluation revealed that IVIG prevented the formation of acanthylosis with IgG deposition in the intercellular spaces. These results point to the efficacy of IVIG in the prevention of blister formation in an experimental PV model.<\/jats:p>","DOI":"10.1111\/j.1365-2249.2005.02947.x","type":"journal-article","created":{"date-parts":[[2005,10,6]],"date-time":"2005-10-06T12:55:38Z","timestamp":1128603338000},"page":"426-432","source":"Crossref","is-referenced-by-count":23,"title":["Protective effect of intravenous immunoglobulin (IVIG) in an experimental model of pemphigus vulgaris"],"prefix":"10.1093","volume":"142","author":[{"given":"D","family":"Mimouni","sequence":"first","affiliation":[{"name":"Department of Medicine B and Center for Autoimmune Diseases, Sheba Medical Center, Tel Hashomer, and the Sackler Faculty of Medicine, Tel Aviv University, Israel"},{"name":"Department of Dermatology, Rabin Medical Center, Petah Tiqva and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Blank","sequence":"additional","affiliation":[{"name":"Department of Medicine B and Center for Autoimmune Diseases, Sheba Medical Center, Tel Hashomer, and the Sackler Faculty of Medicine, Tel Aviv University, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Ashkenazi","sequence":"additional","affiliation":[{"name":"Department of Medicine B and Center for Autoimmune Diseases, Sheba Medical Center, Tel Hashomer, and the Sackler Faculty of Medicine, Tel Aviv University, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y","family":"Milner","sequence":"additional","affiliation":[{"name":"Myers Skin Biochemistry Laboratory, Department of Biological Chemistry, The Hebrew University, Givat Ram, Jerusalem, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Frusic-Zlotkin","sequence":"additional","affiliation":[{"name":"Myers Skin Biochemistry Laboratory, Department of Biological Chemistry, The Hebrew University, Givat Ram, Jerusalem, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G J","family":"Anhalt","sequence":"additional","affiliation":[{"name":"Department of Dermatology, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"David","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Rabin Medical Center, Petah Tiqva and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y","family":"Shoenfeld","sequence":"additional","affiliation":[{"name":"Incumbent of the Laura Schwarz-Kipp Chair for Autoimmunity, Tel Aviv University, Israel"},{"name":"Department of Medicine B and Center for Autoimmune Diseases, Sheba Medical Center, Tel Hashomer, and the Sackler Faculty of Medicine, Tel Aviv University, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2005,10,6]]},"reference":[{"key":"2022010711175518300_b1","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJM198205203062001","article-title":"Induction of pemphigus in neonatal mice by passive transfer of IgG from patients with the disease","volume":"306","author":"Anhalt","year":"1982","journal-title":"N Engl J Med"},{"key":"2022010711175518300_b2","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1172\/JCI117349","article-title":"Absorption of pathogenic autoantibodies by the extracellular domain of pemphigus vulgaris antigen (Dsg3) produced by baculovirus","volume":"94","author":"Amagai","year":"1994","journal-title":"J Clin Invest"},{"key":"2022010711175518300_b3","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.4049\/jimmunol.159.4.2010","article-title":"Characterization of autoantibodies in pemphigus using antigen-specific enzyme-linked immunosorbent assays with baculovirus-expressed recombinant desmogleins","volume":"159","author":"Ishii","year":"1997","journal-title":"J Immunol"},{"key":"2022010711175518300_b4","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1046\/j.1529-8019.2002.01545.x","article-title":"Pemphigus","volume":"15","author":"Mimouni","year":"2002","journal-title":"Dermatol Ther"},{"key":"2022010711175518300_b5","first-page":"654","article-title":"Pemphigus","volume-title":"Fitzpatrick's dermatology in general medicine","author":"Stanley","year":"1999","edition":"5th edn"},{"key":"2022010711175518300_b6","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1046\/j.1365-3148.2002.00360.x","article-title":"In vitro antiviral and antibacterial activity of commercial intravenous immunoglobulin preparations \u2212 a potential role for adjuvant intravenous immunoglobulin therapy in infectious diseases","volume":"12","author":"Krause","year":"2002","journal-title":"Transfus Med"},{"key":"2022010711175518300_b7","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1056\/NEJMra993360","article-title":"Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin","volume":"345","author":"Kazatchkine","year":"2001","journal-title":"N Engl J Med"},{"key":"2022010711175518300_b8","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S0140-6736(84)90701-3","article-title":"Anti-idiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin","volume":"2","author":"Sultan","year":"1984","journal-title":"Lancet"},{"key":"2022010711175518300_b9","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1023\/A:1023239904856","article-title":"Anti-DNA and antiphospholipid antibodies in IVIG preparations: in vivo study in naive mice","volume":"18","author":"Krause","year":"1998","journal-title":"J Clin Immunol"},{"key":"2022010711175518300_b10","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/BF00918187","article-title":"Detection and purification of antiidiotypic antibody against anti-DNA in intravenous immune globulin","volume":"11","author":"Evans","year":"1991","journal-title":"J Clin Immunopathol"},{"key":"2022010711175518300_b11","doi-asserted-by":"crossref","first-page":"4104","DOI":"10.4049\/jimmunol.143.12.4104","article-title":"Antiidiotypes against autoantibodies in pooled normal human polyspecific IgG","volume":"143","author":"Rossi","year":"1989","journal-title":"J Immunol"},{"key":"2022010711175518300_b12","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/j.1365-2249.1991.tb05631.x","article-title":"Anti-idiotypes against anti-neutrophil cytoplasmic antigen autoantibodies in normal human polyspecific IgG for therapeutic use and in the remission sera of patients with systemic vasculitis","volume":"83","author":"Rossi","year":"1991","journal-title":"Clin Exp Immunol"},{"key":"2022010711175518300_b13","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/0896-8411(92)90153-H","article-title":"Analysis of anti-idiotypic antibodies against anti-microsomal antibodies in patients with thyroid autoimmunity","volume":"5","author":"Tandon","year":"1992","journal-title":"J Autoimmun"},{"key":"2022010711175518300_b14","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1006\/clin.1993.1064","article-title":"Spontaneous recovery from the Guillain\u2013Barre syndrome is associated with anti-idiotypic antibodies recognizing a cross-reactive idiotype on anti-neuroblastoma cell line antibodies","volume":"67","author":"Lundkvist","year":"1993","journal-title":"Clin Immunol Immunopathol"},{"key":"2022010711175518300_b15","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1006\/jaut.1994.1039","article-title":"Anti-idiotypes against antiphospholipid antibodies are present in normal polyspecific immunoglobulins for therapeutic use","volume":"7","author":"Caccavo","year":"1994","journal-title":"J Autoimmun"},{"key":"2022010711175518300_b16","first-page":"46","article-title":"In-vitro inhibition of antiplatelet autoantibodies by intravenous immunoglobulins and Rh immunoglobulins","volume":"42","author":"Mehta","year":"1996","journal-title":"J Postgrad Med"},{"key":"2022010711175518300_b17","first-page":"587","article-title":"Pooled human immunoglobulins contain anti-idiotypes with reactivity against the SLE-associated 4B4 cross-reactive idiotype","volume":"14","author":"DeKeyser","year":"1996","journal-title":"Clin Exp Rheumatol"},{"key":"2022010711175518300_b18","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/0022-510X(96)00053-6","article-title":"Possible mechanism of intravenous immunoglobulin treatment on anti-GM1 antibody-mediated neuropathies","volume":"139","author":"Yuki","year":"1996","journal-title":"J Neurol Sci"},{"key":"2022010711175518300_b19","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1023\/B:JOCI.0000019809.55787.ec","article-title":"IVIG for autoimmune, fibrosis, and malignant conditions. our experience with 200 patients","volume":"24","author":"Shoenfeld","year":"2004","journal-title":"J Clin Immunol"},{"key":"2022010711175518300_b20","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1191\/096120399678841007","article-title":"A study of 20 SLE patients with intravenous immunoglobulin \u2212 clinical and serological response","volume":"8","author":"Levy","year":"1999","journal-title":"Lupus"},{"key":"2022010711175518300_b21","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3109\/08820130009060871","article-title":"Detection of antibodies to gangliosides and glycolipids in various intravenous immunoglobulin (IVIg) preparations","volume":"29","author":"Terryberry","year":"2000","journal-title":"Immunol Invest"},{"key":"2022010711175518300_b22","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1191\/096120301701549705","article-title":"Antiphospholipid antibody levels in intravenous immunoglobulin (IVIG) preparations","volume":"10","author":"Sherer","year":"2001","journal-title":"Lupus"},{"key":"2022010711175518300_b23","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1365-2249.1994.tb06573.x","article-title":"Pathogenic anti-DNA idiotype-reactive IgG in intravenous immunoglobulin preparations","volume":"97","author":"Silvestris","year":"1994","journal-title":"Clin Exp Immunol"},{"key":"2022010711175518300_b24","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1177\/096120339300200607","article-title":"In vitro modulation of anti-DNA secreting peripheral blood mononuclear cells of lupus patients by anti-idiotypic antibody of pooled human intravenous immune globulin","volume":"2","author":"Evans","year":"1993","journal-title":"Lupus"},{"key":"2022010711175518300_b25","first-page":"538","article-title":"Suppression of anti-DNA antibody production in MRL mice by treatment with anti-idiotypic antibodies","volume":"70","author":"Mahana","year":"1987","journal-title":"Clin Exp Immunol"},{"key":"2022010711175518300_b26","doi-asserted-by":"crossref","first-page":"187","DOI":"10.4049\/jimmunol.132.1.187","article-title":"Suppression of murine lupus nephritis by administration of an anti-idiotypic antibody to anti-DNA","volume":"132","author":"Hahn","year":"1984","journal-title":"J Immunol"},{"key":"2022010711175518300_b27","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/j.1365-2249.1991.tb05601.x","article-title":"Anti-idiotype and immunosuppressant treatment of murine lupus","volume":"83","author":"Morland","year":"1991","journal-title":"Clin Exp Immunol"},{"key":"2022010711175518300_b28","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/nm0104-17","article-title":"The idiotypic network in autoimmunity: antibodies that bind antibodies that bind antibodies","volume":"10","author":"Shoenfeld","year":"2004","journal-title":"Nat Med"},{"key":"2022010711175518300_b29","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1093\/intimm\/dxf099","article-title":"Efficacy of IVIG affinity-purified anti-double-stranded DNA anti-idiotypic antibodies in the treatment of an experimental murine model of systemic lupus erythematosus","volume":"14","author":"Shoenfeld","year":"2002","journal-title":"Int Immunol"},{"key":"2022010711175518300_b30","first-page":"377","article-title":"Influence of intravenous immunoglobulin therapy on autoantibody titers to desmoglein 3 and desmoglein 1 in pemphigus vulgaris","volume":"13","author":"Sami","year":"2003","journal-title":"Eur J Dermatol"},{"key":"2022010711175518300_b31","first-page":"48","article-title":"Serum levels of autoantibodies to desmoglein 3 in patients with therapy-resistant pemphigus vulgaris successfully treated with adjuvant intravenous immunoglobulins","volume":"84","author":"Herzog","year":"2004","journal-title":"Acta Derm Venereol"},{"key":"2022010711175518300_b32","first-page":"14","article-title":"Preparation and purification of active fragments from mouse monoclonal antibodies","volume-title":"Handbook of experimental immunology","author":"Parham","year":"1994"},{"key":"2022010711175518300_b33","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/1523-1747.ep12343081","article-title":"Pemphigus vulgaris antigen (Desmoglein 3) is localized in the lower epidermis, the site of blister formation in patients","volume":"106","author":"Amagai","year":"1996","journal-title":"J Invest Dermatol"},{"key":"2022010711175518300_b34","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1046\/j.1365-2133.2002.04838.x","article-title":"Monitoring disease activity in pemphigus with enzyme-linked immunosorbent assay using recombinant desmogleins 1 and 3","volume":"147","author":"Cheng","year":"2002","journal-title":"Br J Dermatol"},{"key":"2022010711175518300_b35","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1034\/j.1600-0625.2000.009004229.x","article-title":"Cloning of the mouse desmoglein 3 gene (Dsg3): interspecies conservation within the cadherin superfamily","volume":"9","author":"Ishikawa","year":"2000","journal-title":"Exp Dermatol"},{"key":"2022010711175518300_b36","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1172\/JCI3647","article-title":"Antibodies against desmoglein 3 (pemphigus vulgaris antigen) are present in sera from patients with paraneoplastic pemphigus and cause acantholysis in vivo in neonatal mice","volume":"102","author":"Amagai","year":"1998","journal-title":"J Clin Invest"},{"key":"2022010711175518300_b37","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/1523-1747.ep12513454","article-title":"Production of epidermal acantholysis in normal human skin in vitro by the IgG fraction from pemphigus serum","volume":"67","author":"Schiltz","year":"1976","journal-title":"J Invest Dermatol"},{"key":"2022010711175518300_b38","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1084\/jem.157.1.259","article-title":"Anti-cell surface pemphigus autoantibody stimulates plasminogen activator activity of human epidermal cells","volume":"157","author":"Hashimoto","year":"1983","journal-title":"J Exp Med"},{"key":"2022010711175518300_b39","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1001\/archderm.138.9.1158","article-title":"Corticosteroid-sparing effect of intravenous immunoglobulin therapy in patients with pemphigus vulgaris","volume":"138","author":"Sami","year":"2002","journal-title":"Arch Dermatol"},{"key":"2022010711175518300_b40","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1067\/mjd.2002.122735","article-title":"Treatment of pemphigus with intravenous immunoglobulin","volume":"47","author":"Bystryn","year":"2002","journal-title":"J Am Acad Dermatol"}],"container-title":["Clinical and Experimental Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2249.2005.02947.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/142\/3\/426\/42078430\/j.1365-2249.2005.02947.x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/142\/3\/426\/42078430\/j.1365-2249.2005.02947.x.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T00:26:14Z","timestamp":1683246374000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cei\/article\/142\/3\/426\/6440346"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,9,11]]},"references-count":40,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2005,10,6]]},"published-print":{"date-parts":[[2005,9,11]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2249.2005.02947.x","relation":{},"ISSN":["1365-2249","0009-9104"],"issn-type":[{"value":"1365-2249","type":"electronic"},{"value":"0009-9104","type":"print"}],"subject":[],"published-other":{"date-parts":[[2005,12]]},"published":{"date-parts":[[2005,9,11]]}}}